MedCity News January 9, 2025
Transcarent is planning to acquire Accolade for $621 million, the companies announced Wednesday. The two companies are very complementary and the deal gives Accolade a chance to turn things around after struggling in the public market, experts say.
A notable marriage is occurring in the world of digital health: Transcarent has claimed Accolade for $621 million. But by no means is this a marriage of equals given how the latter is being taken private after faltering in its aim to achieve profitability.
During the pandemic, care navigation company Accolade’s stock was trading at nearly $60, a far cry from all of last year when the stock formally sank into the single digits. The Seattle company offers virtual primary care and...
Today's Sponsors
Today's Sponsor